These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21474175)

  • 1. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting.
    Thomann JS; Heurtault B; Weidner S; Brayé M; Beyrath J; Fournel S; Schuber F; Frisch B
    Biomaterials; 2011 Jul; 32(20):4574-83. PubMed ID: 21474175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct.
    Roth A; Rohrbach F; Weth R; Frisch B; Schuber F; Wels WS
    Br J Cancer; 2005 Apr; 92(8):1421-9. PubMed ID: 15812545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Essential roles of tumor-derived helper T cell epitopes for an effective peptide-based tumor vaccine.
    Wang L; Miyahara Y; Kato T; Wang L; Aota T; Kuribayashi K; Shiku H
    Cancer Immun; 2003 Nov; 3():16. PubMed ID: 14629132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of thiol-reactive lipopeptide adjuvants. Incorporation into liposomes and study of their mitogenic effect on mouse splenocytes.
    Roth A; Espuelas S; Thumann C; Frisch B; Schuber F
    Bioconjug Chem; 2004; 15(3):541-53. PubMed ID: 15149182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.
    Fehres CM; Kalay H; Bruijns SC; Musaafir SA; Ambrosini M; van Bloois L; van Vliet SJ; Storm G; Garcia-Vallejo JJ; van Kooyk Y
    J Control Release; 2015 Apr; 203():67-76. PubMed ID: 25656175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of neo-glycoconjugates that target the mannose receptor and enhance TLR-independent cross-presentation and Th1 polarization.
    Singh SK; Streng-Ouwehand I; Litjens M; Kalay H; Burgdorf S; Saeland E; Kurts C; Unger WW; van Kooyk Y
    Eur J Immunol; 2011 Apr; 41(4):916-25. PubMed ID: 21400496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
    Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
    Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas.
    Gu XG; Schmitt M; Hiasa A; Nagata Y; Ikeda H; Sasaki Y; Akiyoshi K; Sunamoto J; Nakamura H; Kuribayashi K; Shiku H
    Cancer Res; 1998 Aug; 58(15):3385-90. PubMed ID: 9699670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of synthetic lipopeptides formulated in liposomes on the maturation of human dendritic cells.
    Espuelas S; Roth A; Thumann C; Frisch B; Schuber F
    Mol Immunol; 2005 Apr; 42(6):721-9. PubMed ID: 15781116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mannosylated liposomes for targeted vaccines delivery.
    Vyas SP; Goyal AK; Khatri K
    Methods Mol Biol; 2010; 605():177-88. PubMed ID: 20072881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine.
    He LZ; Weidlick J; Sisson C; Marsh HC; Keler T
    Cell Mol Immunol; 2015 Nov; 12(6):719-28. PubMed ID: 25345808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells.
    Toes RE; van der Voort EI; Schoenberger SP; Drijfhout JW; van Bloois L; Storm G; Kast WM; Offringa R; Melief CJ
    J Immunol; 1998 May; 160(9):4449-56. PubMed ID: 9574550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.
    Jérôme V; Graser A; Müller R; Kontermann RE; Konur A
    J Immunother; 2006; 29(3):294-305. PubMed ID: 16699372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors.
    Nava-Parada P; Forni G; Knutson KL; Pease LR; Celis E
    Cancer Res; 2007 Feb; 67(3):1326-34. PubMed ID: 17283170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
    Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
    Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination.
    Bal SM; Hortensius S; Ding Z; Jiskoot W; Bouwstra JA
    Vaccine; 2011 Jan; 29(5):1045-52. PubMed ID: 21129393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal constructs for antitumoral vaccination by the nasal route.
    Kakhi Z; Frisch B; Heurtault B; Pons F
    Biochimie; 2016 Nov; 130():14-22. PubMed ID: 27423321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
    Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
    Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.
    Toes RE; Blom RJ; Offringa R; Kast WM; Melief CJ
    J Immunol; 1996 May; 156(10):3911-8. PubMed ID: 8621930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.